var data={"title":"Cefixime: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cefixime: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5839?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cefixime-drug-information\" class=\"drug drug_general\">see &quot;Cefixime: Drug information&quot;</a> and <a href=\"topic.htm?path=cefixime-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cefixime: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147405\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Suprax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147406\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Auro-Cefixime;</li>\n      <li>Suprax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045954\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Cephalosporin (Third Generation)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045946\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cefixime-drug-information\" class=\"drug drug_general\">see &quot;Cefixime: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Suprax 400 mg tablets have been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Unless otherwise specified, any dosage form may be used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing; susceptible infection (mild to moderate):</b> Infants, Children, and Adolescents: Oral: 8 mg/kg/day divided every 12 to 24 hours; maximum daily dose: 400 mg/<b>day</b> (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Febrile neutropenia (low-risk):</b> Limited data available: Infants, Children, and Adolescents: Oral: 8 mg/kg/day in divided doses every 12 to 24 hours; in most trials, cefixime therapy was initiated as step-down therapy after 48 to 72 hours of empiric parenteral antibiotic therapy with first cefixime dose administered at the end of the last IV infusion (Klaassen 2000; Lehrnbecher 2017; Paganini 2000; Shenep 2001). <b>Note:</b> In clinical trials, doses were repeated if patient vomited within 2 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gonococcal infection, uncomplicated</b> <b>infections of the cervix, urethra, or rectum: </b>Children &ge;45 kg and Adolescents: Oral: 400 mg as a single dose in combination with oral azithromycin as a single dose (CDC [Workowski 2015]). <b>Note:</b> CDC no longer recommends cefixime as a first-line agent (ceftriaxone is the preferred cephalosporin in combination with azithromycin); cefixime should only be used if ceftriaxone is unavailable. In addition, cefixime is not an option for the treatment of uncomplicated gonorrhea of the pharynx due to limited efficacy; if it must be used instead of ceftriaxone, a test-of-cure follow up should be performed 14 days after treatment (CDC [Workowski 2015]). In Canada, due to increased antimicrobial resistance, the Public Health Agency of Canada recommends 800 mg as a single dose for treatment of uncomplicated gonococcal infections (Public Health Agency of Canada 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Irinotecan-associated diarrhea, prophylaxis:</b> Limited data available: Infants, Children, and Adolescents: Oral: 8 mg/kg once daily; begin 5 days before oral irinotecan therapy and continue throughout course (Wagner 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Otitis media, acute:</b> Oral suspension or chewable tablets: Infants, Children, and Adolescents: Oral: 8 mg/kg/day divided every 12 to 24 hours; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pharyngitis or tonsillitis; <i>S. pyogenes</i>:</b> <b>Note:</b> Not preferred for treatment in IDSA Guidelines due to unnecessary broad spectrum, and lack of selectivity for antibiotic resistant flora (IDSA [Schulman 2012]); Infants, Children, and Adolescents: Oral: 8 mg/kg/day in divided doses every 12 to 24 hours for &ge;10 days; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community-acquired (CAP); <i>haemophilus influenza</i> types A-F or nontypeable; mild infection or step-down therapy:</b> Infants &ge;3 months, Children, and Adolescents: Oral: 8 mg/kg/day in divided doses every 12 to 24 hours; maximum daily dose: 400 mg/<b>day </b>(IDSA/PIDS [Bradley 2011]) <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rhinosinusitis, acute bacterial:</b> Infants, Children, and Adolescents: Oral: 4 mg/kg/dose every 12 hours with concomitant clindamycin for 10 to 14 days; maximum daily dose: 400 mg/<b>day</b>. <b>Note:</b> Recommended in patients with non-type I penicillin allergy, after failure of initial therapy or in patients at risk for antibiotic resistance (eg, daycare attendance, age &lt;2 years, recent hospitalization, antibiotic use within the past month) (Chow 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Typhoid fever (<i>Salmonella typhi</i>):</b> Limited data available; efficacy results variable: Infants, Children and Adolescents: Oral: 7.5 to 10 mg/kg/dose every 12 hours for 7 to 14 days (Cao 1999; Girgis 1995; Stephens 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection; acute:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Infants &ge;6 months, Children, and Adolescents: 8 mg/kg/day in divided doses every 12 to 24 hours; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Infants &ge;2 months and Children &le;2 years: Initial: 8 mg/kg/day every 24 hours for 7 to 14 days; in patients &lt;24 months, shorter courses (1 to 3 days) have been shown to be inferior to longer durations of therapy (AAP 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing; susceptible infections:</b> Oral: 400 mg daily in divided doses every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gonococcal infection, uncomplicated infections of cervix, urethra, or rectum:</b> Oral: 400 mg as a single dose in combination with oral azithromycin as a single dose (CDC [Workowski 2015]). <b>Note:</b> CDC no longer recommends cefixime as a first-line agent (ceftriaxone is the preferred cephalosporin); cefixime should only be used if ceftriaxone is unavailable. In addition, cefixime is <b>not</b> an option for the treatment of uncomplicated gonorrhea of the pharynx due to limited efficacy; if it must be used instead of ceftriaxone, a test-of-cure follow up should be performed 14 days after treatment (CDC [Workowski 2015]). In Canada, due to increased antimicrobial resistance, the Public Health Agency of Canada recommends 800 mg as a single dose for treatment of uncomplicated gonococcal infections (Public Health Agency of Canada 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gonococcal infection, expedited partner therapy:</b> Oral: 400 mg as a single dose in combination with oral azithromycin (CDC [Workowski 2015]). <b>Note:</b> To be used only for heterosexual partners with gonorrhea if health department partner-management strategies are impractical/unavailable and there is concern by the provider for the prompt evaluation and treatment of the partner; medication may be delivered to partner by patient, collaborating pharmacy, or disease investigation specialist as permitted by law; written materials to educate partners about their exposure to gonorrhea, importance of therapy, and when to seek clinical evaluation for adverse reactions/complications must also be provided with the medication (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>S. pyogenes</i> infections:</b> Oral: 400 mg daily in divided doses every 12 to 24 hours for &ge;10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;6 months, Children, and Adolescents: Very limited data available; some clinicians have suggested the following (Daschner 2005; Dhib 1991):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate impairment: No adjustment recommended</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe impairment (eg, GFR &le;10 to 20 mL/minute/1.73 m<sup>2</sup>): Reduce dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Anuric: Reduce dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis, peritoneal dialysis: Not significantly removed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;60 mL/minute: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 21 to 59 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Chewable tablet, tablet: Not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Suspension: 260 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;20 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Chewable tablet, tablet: 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">100 mg/5 mL suspension: 172 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">200 mg/5 mL suspension: 176 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">500 mg/5 mL suspension: 180 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: Not significantly removed:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Chewable tablet, tablet: Not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Suspension: 260 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CAPD: Not significantly removed by peritoneal dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Chewable tablet, tablet: 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">100 mg/5 mL suspension: 172 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">200 mg/5 mL suspension: 176 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">500 mg/5 mL suspension: 180 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147381\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suprax: 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suprax: 100 mg/5 mL (50 mL) [strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suprax: 200 mg/5 mL (50 mL, 75 mL); 500 mg/5 mL (10 mL, 20 mL) [contains sodium benzoate; strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/5 mL (50 mL); 200 mg/5 mL (50 mL, 75 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suprax: 400 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suprax: 100 mg, 200 mg [contains aspartame, fd&amp;c red #40 aluminum lake; tutti-frutti flavor]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147365\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28606289\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Suprax 400 mg tablets have been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045958\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered with or without food; administer with food to decrease GI distress; shake suspension well before use; chewable tablets must be chewed or crushed before swallowing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147400\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, chewable tablet, tablet: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for suspension: Prior to reconstitution, store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).  After reconstitution, suspension may be stored for 14 days at room temperature or under refrigeration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045957\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of urinary tract infections, otitis media, acute exacerbations of chronic bronchitis due to susceptible organisms which may include <i>S. pneumoniae</i> and <i>pyogenes</i>, <i>H. influenzae</i>, <i>M. catarrhalis</i>, <i>E. coli</i>, and <i>P mirabilis</i>; treatment of pharyngitis and tonsillitis due to <i>S. pyogenes</i>; treatment of uncomplicated cervical/urethral gonorrhea due to <i>N. gonorrhoeae</i> (All indications: FDA approved in ages &ge;6 months and adults); has also been used for management of irinotecan-associated diarrhea, prophylaxis for sexual victimization, and management of low risk febrile neutropenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Due to concerns of resistance, the CDC no longer recommends use of cefixime as a first-line regimen in the treatment of uncomplicated gonorrhea in the US; ceftriaxone is the preferred cephalosporin in combination with azithromycin (CDC 2012; CDC [Workowski 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147450\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cefixime may be confused with cefepime </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suprax may be confused with Sporanox</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cefiton: Brand name for cefixime [Portugal] may be confused with Ceftim brand name for ceftazidime [Portugal]; Ceftime brand name for ceftazidime [Thailand]; Ceftin brand name for cefuroxime [US, Canada]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147448\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, flatulence, loose stools, nausea </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Acute renal failure, anaphylactoid reaction, anaphylaxis, angioedema, candidiasis, dizziness, drug fever, eosinophilia, erythema multiforme, facial edema, fever, headache, hepatitis, hyperbilirubinemia, increased blood urea nitrogen, increased serum creatinine, increased serum transaminases, jaundice, leukopenia, neutropenia, prolonged prothrombin time, pruritus, pseudomembranous colitis, seizure, serum sickness-like reaction, skin rash, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria, vaginitis, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147388\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cefixime, any component of the formulation, or other cephalosporins or penicillins</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147369\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Severe cutaneous reactions (eg, toxic epidermal necrolysis, Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms [DRESS]) have been reported. If a reaction occurs, discontinue and institute supportive therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemolytic anemia: Immune-mediated hemolytic anemia (including fatalities) have been reported. Monitor patient (including hematologic parameters and drug-induced antibody testing when clinically appropriate) during and for 2 to 3 weeks after therapy. If hemolytic anemia occurs during therapy, discontinue use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity and anaphylaxis have been reported in patients receiving beta-lactam drugs. Use caution in patients with a history of hypersensitivity to cephalosporins, penicillins, or other beta-lactams. If administered to penicillin-sensitive patients, use with caution and discontinue use if allergic reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal failure: May cause acute renal failure including tubulointerstitial nephritis. If renal failure occurs, discontinue and initiate appropriate supportive therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; may increase the risk of seizures if dosage not reduced; modify dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with a history of gastrointestinal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemolytic anemia: Should not be administered to patients with a history of cephalosporin-associated hemolytic anemia; recurrence of hemolysis is more severe.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Chewable tablets contain phenylalanine; avoid use or use with caution in patients with phenylketonuria (PKU).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855358\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May cause diarrhea; reported incidence (~16%) similar in children receiving oral suspension and adults receiving tablet dosage form. Use caution when interchanging product formulations; oral suspension and chewable tablets are bioequivalent but oral immediate release tablets are not bioequivalent; for some infections (eg, otitis media), dosing recommendations are product specific. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298989\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147374\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13127&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147401\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food delays cefixime absorption. Management: May administer with or without food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147377\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5951284\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects were not observed in animal reproduction studies. Cefixime crosses the placenta and can be detected in the amniotic fluid (Ozy&uuml;nc&uuml; 2010). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045953\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">With prolonged therapy, monitor renal and hepatic function periodically; number and type of stools/day for diarrhea. Observe for signs and symptoms of anaphylaxis during first dose. When used as part of alternative treatment for gonococcal infection, test-of-cure 7 days after dose (CDC 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147368\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147387\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Chewable tablets and oral suspension are bioequivalent. However, oral suspension and tablet (nonchewable)/capsule formulations are <b>not</b> considered bioequivalent (oral suspension AUC ~10% to 25% greater compared with tablet after doses of 100-400 mg in normal adult volunteers).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Absorption: 40% to 50%; <b>Note:</b> Capsule AUC reduced by ~15% and C<sub>max</sub> by ~25% when taken with food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely throughout the body and reaches therapeutic concentration in most tissues and body fluids, including synovial, pericardial, pleural, peritoneal; bile, sputum, and urine; bone, myocardium, gallbladder, and skin and soft tissue </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 65% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Normal renal function: 3 to 4 hours;  Moderate impairment (CrCl  20 to 40 mL/minute): 6.4 hours; Renal failure: Up to 11.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Tablet, suspension: 2 to 6 hours; Capsule: 3 to 8 hours; Delayed with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (50% of absorbed dose as active drug); feces (10%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6133204\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Suprax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (10): $276.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Suprax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (10): $234.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (10): $468.71</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Cefixime Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (50 mL): $222.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL (50 mL): $445.39</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Suprax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (50 mL): $272.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL (50 mL): $544.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/5 mL (10 mL): $272.21</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147393\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aerocef (AT);</li>\n      <li>Anfix (ID);</li>\n      <li>Bicebid (VN);</li>\n      <li>Cavlis (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Cefarox (ID);</li>\n      <li>Cefexin (HR);</li>\n      <li>Cefiac (BD);</li>\n      <li>Cefiget (VN);</li>\n      <li>Cefim (BD, ET, KW);</li>\n      <li>Cefimark (VN);</li>\n      <li>Cefimed (ET);</li>\n      <li>Cefirax (KR);</li>\n      <li>Cefix (AE, BH, CY, EG, ET, IQ, IR, JO, KR, KW, LB, LY, MY, OM, SA, SY, YE);</li>\n      <li>Cefixmycin (PH, TW);</li>\n      <li>Cefspan (CN, ID, JP, PK, TH, TW, VN);</li>\n      <li>Ceftoral (GR);</li>\n      <li>Cephoral (CH, DE);</li>\n      <li>Cerafix (ID);</li>\n      <li>Cexim (TW);</li>\n      <li>Cexima (PY);</li>\n      <li>Chifix (LK);</li>\n      <li>Cifacure (PH);</li>\n      <li>Cifex (TR);</li>\n      <li>Denvar (CR, DO, ES, GT, HN, MX, NI, PA, SV);</li>\n      <li>Devoxim (CO);</li>\n      <li>Edixim (HR);</li>\n      <li>Eficef (RO);</li>\n      <li>Fix A (BD);</li>\n      <li>Fix-A (PH);</li>\n      <li>Fixcef (PH);</li>\n      <li>Fixef (ID);</li>\n      <li>Fixim (CR, DO, GT, HN, LB, NI, NL, PA, SV);</li>\n      <li>Fixime (ZA);</li>\n      <li>Fixiphar (ID);</li>\n      <li>Fixitil-T (LK);</li>\n      <li>Fixx (IN);</li>\n      <li>Flamifiks (UA);</li>\n      <li>Hafixim (VN);</li>\n      <li>Ikzym (UA);</li>\n      <li>Ixime (AE, MY);</li>\n      <li>Lanfix (ID);</li>\n      <li>Longacef (VE);</li>\n      <li>Lopraks (UA);</li>\n      <li>Magnacef (AE, BH, JO, LB, QA, SA);</li>\n      <li>Maxicef (PE);</li>\n      <li>Maxpro (ID);</li>\n      <li>Minixime (MY);</li>\n      <li>Mycefix (PH);</li>\n      <li>Neocef (PT);</li>\n      <li>Novacef (AR);</li>\n      <li>Oralcef (PY);</li>\n      <li>Oroken (FR);</li>\n      <li>Pancef (BG);</li>\n      <li>Savecef (LK);</li>\n      <li>Septipan (PH);</li>\n      <li>Simfix (ID);</li>\n      <li>Sixime (TH);</li>\n      <li>Sofix (ID);</li>\n      <li>Sortsef (UA);</li>\n      <li>Spaxim (ID);</li>\n      <li>Starcef (ID);</li>\n      <li>Supracef (FI);</li>\n      <li>Supran (IL);</li>\n      <li>Suprax (AE, BB, BH, CZ, DE, EG, GB, HU, IE, IT, JO, KR, KW, LB, QA, RU, SA, SK, TR);</li>\n      <li>Surixime (PH);</li>\n      <li>Tadix (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Taxocef-O (PH);</li>\n      <li>Tergecef (PH);</li>\n      <li>Tocef (ID);</li>\n      <li>Topcef (LK);</li>\n      <li>Tricef (BD, CL, MT, PT, SE, TR);</li>\n      <li>Ultraxime (PH);</li>\n      <li>Urticef (ID);</li>\n      <li>Vineks (UA);</li>\n      <li>Vipime (LK);</li>\n      <li>Winex (AE, KW, LB, QA, SA);</li>\n      <li>Xifia (RO);</li>\n      <li>Yafix (ID);</li>\n      <li>Zefral (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Subcommittee on Urinary Tract Infection. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i>Pediatrics</i>. 2011;128(3):595-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/21873693/pubmed\" target=\"_blank\" id=\"21873693\">21873693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cao XT, Kneen R, Nguyen TA, et al, &quot;A Comparative Study of Ofloxacin and Cefixime for Treatment of Typhoid Fever in Children. The Dong Nai Pediatric Center Typhoid Study Group,&quot; <i>Pediatr Infect Dis J</i>, 1999, 18(3):245-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/10093945/pubmed\" target=\"_blank\" id=\"10093945\">10093945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Sexually Transmitted Diseases Treatment Guidelines, 2010,&quot; <i>MMWR Recomm Rep</i>, 2010, 59(RR-12):1-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/21160459/pubmed\" target=\"_blank\" id=\"21160459\">21160459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections&rdquo;, <i>MMWR Morb Mortal Wkly Rep</i>, 2012, 61(31):590-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/22874837/pubmed\" target=\"_blank\" id=\"22874837\">22874837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo; <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daschner M. Drug dosage in children with reduced renal function. <i>Pediatr Nephrol</i>. 2005;20:1675-1686.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/16133064/pubmed\" target=\"_blank\" id=\"16133064\">16133064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dhib M, Moulin B, Leroy A, et al. Relationship between renal function and disposition of oral cefixime. <i>Eur J Clin Pharmacol</i>. 1991;41:579-583.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/1815970/pubmed\" target=\"_blank\" id=\"1815970\">1815970</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Girgis NI, Sultan Y, Hammad O, et al, &quot;Comparison of the Efficacy, Safety and Cost of Cefixime, Ceftriaxone and Aztreonam in the Treatment of Multidrug-Resistant <i>Salmonella typhi</i> Septicemia in Children,&quot; <i>Pediatr Infect Dis J</i>, 1995, 14(7):603-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/7567290/pubmed\" target=\"_blank\" id=\"7567290\">7567290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guay DRP, Meatherall RC, Harding GK, et al. Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency. <i>Antimicrob Agents Chemother</i>. 1986;30(3):485-490.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/3777912/pubmed\" target=\"_blank\" id=\"3777912\">3777912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klaassen RJ, Allen U, and Doyle JJ, &quot;Randomized Placebo-Controlled Trial of Oral Antibiotics in Pediatric Oncology Patients at Low-Risk With Fever and Neutropenia,&quot; <i>J Pediatr Hematol Oncol</i>, 2000, 22(5):405-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/11037850/pubmed\" target=\"_blank\" id=\"11037850\">11037850</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. <i>J Clin Oncol</i>. 2017;35(18):2082-2094.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/28459614/pubmed\" target=\"_blank\" id=\"28459614\">28459614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozy&uuml;nc&uuml; O, Beksac MS, Nemutlu E, et al, &quot;Maternal Blood and Amniotic Fluid Levels of Moxifloxacin, Levofloxacin and Cefixime,&quot; <i>J Obstet Gynaecol Res</i>, 2010, 36(3):484-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/20598025/pubmed\" target=\"_blank\" id=\"20598025\">20598025</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paganini HR, Sarkis CM, De Martino MG, et al, &quot;Oral Administration of Cefixime to Lower Risk Febrile Neutropenic Children With Cancer,&quot; <i>Cancer</i>, 2000, 88(12):2848-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/10870071/pubmed\" target=\"_blank\" id=\"10870071\">10870071</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Public Health Agency of Canada, &ldquo;Canadian Guidelines on Sexually Transmitted Infections.&quot; Available at http://www.phac-aspc.gc.ca/std-mts/sti-its/alert/2011/alert-gono-eng.php. Accessed January 4, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shenep JL, Flynn PM, Baker DK, et al, &quot;Oral Cefixime Is Similar to Continued Intravenous Antibiotics in the Empirical Treatment of Febrile Neutropenic Children With Cancer,&quot; <i>Clin Infect Dis</i>, 2001, 32(1):36-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/11112678/pubmed\" target=\"_blank\" id=\"11112678\">11112678</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2012;55(10):1279-1282. Erratum in: <i>Clin Infect Dis</i>. 2014;58(10):1496.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/23091044/pubmed\" target=\"_blank\" id=\"23091044\">23091044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stephens I and Levine MM, &quot;Management of Typhoid Fever in Children,&quot; <i>Pediatr Infect Dis J</i>, 2002, 21(2):157-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/11840084/pubmed\" target=\"_blank\" id=\"11840084\">11840084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner LM, Crews KR, Stewart CF, et al, &quot;Reducing Irinotecan-Associated Diarrhea in Children,&quot; <i>Pediatr Blood Cancer</i>, 2008, 50(2):201-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/17570704/pubmed\" target=\"_blank\" id=\"17570704\">17570704</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/26042815 /pubmed\" target=\"_blank\" id=\"26042815 \">26042815 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13127 Version 139.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F147405\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F147406\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045954\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045946\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F147381\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F147365\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F28606289\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045958\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F147400\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045957\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F147450\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F147448\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F147388\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F147369\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855358\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298989\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F147374\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F147401\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F147377\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5951284\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045953\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F147368\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F147387\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F6133204\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F147393\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13127|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cefixime-drug-information\" class=\"drug drug_general\">Cefixime: Drug information</a></li><li><a href=\"topic.htm?path=cefixime-patient-drug-information\" class=\"drug drug_patient\">Cefixime: Patient drug information</a></li></ul></div></div>","javascript":null}